🎉 M&A multiples are live!
Check it out!

Abclon Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abclon and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Abclon Overview

About Abclon

Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.


Founded

2010

HQ

South Korea
Employees

n/a

Website

abclon.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$107M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Abclon Financials

Abclon has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Abclon achieved revenue of $1.6M and an EBITDA of -$9.4M.

Abclon expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Abclon valuation multiples based on analyst estimates

Abclon P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.1M $1.6M XXX XXX XXX
Gross Profit $1.6M $1.5M XXX XXX XXX
Gross Margin 77% 94% XXX XXX XXX
EBITDA -$6.6M -$9.4M XXX XXX XXX
EBITDA Margin -315% -590% XXX XXX XXX
Net Profit -$6.3M -$8.7M XXX XXX XXX
Net Margin -300% -546% XXX XXX XXX
Net Debt $4.3M $0.2M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Abclon Stock Performance

As of April 15, 2025, Abclon's stock price is KRW 9280 (or $6).

Abclon has current market cap of KRW 162B (or $110M), and EV of KRW 158B (or $107M).

See Abclon trading valuation data

Abclon Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$107M $110M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Abclon Valuation Multiples

As of April 15, 2025, Abclon has market cap of $110M and EV of $107M.

Abclon's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Abclon's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Abclon and 10K+ public comps

Abclon Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $107M XXX XXX XXX
EV/Revenue 67.3x XXX XXX XXX
EV/EBITDA -11.4x XXX XXX XXX
P/E -9.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abclon Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Abclon Valuation Multiples

Abclon's NTM/LTM revenue growth is n/a

Abclon's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Abclon's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Abclon's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Abclon and other 10K+ public comps

Abclon Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -24% XXX XXX XXX XXX
EBITDA Margin -590% XXX XXX XXX XXX
EBITDA Growth 42% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 20% XXX XXX XXX XXX
G&A Expenses to Revenue 19% XXX XXX XXX XXX
R&D Expenses to Revenue 572% XXX XXX XXX XXX
Opex to Revenue 712% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Abclon Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Abclon M&A and Investment Activity

Abclon acquired  XXX companies to date.

Last acquisition by Abclon was  XXXXXXXX, XXXXX XXXXX XXXXXX . Abclon acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Abclon

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Abclon

When was Abclon founded? Abclon was founded in 2010.
Where is Abclon headquartered? Abclon is headquartered in South Korea.
Who is the CEO of Abclon? Abclon's CEO is Mr. Jong-seo Lee.
Is Abclon publicy listed? Yes, Abclon is a public company listed on KRX.
What is the stock symbol of Abclon? Abclon trades under 174900 ticker.
When did Abclon go public? Abclon went public in 2017.
Who are competitors of Abclon? Similar companies to Abclon include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Abclon? Abclon's current market cap is $110M
What is the current revenue growth of Abclon? Abclon revenue growth between 2023 and 2024 was -24%.
Is Abclon profitable? Yes, Abclon is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.